Thursday, February 02, 2017 9:03:12 AM
PlasmaVoice:Feb.,2017
GeoVax’s approach to Zika vaccine development uses a recombinant Modified Vaccinia Ankara virus (MVA) viral vector to produce virus-like particles (VLPs) in the person being vaccinated. The production of VLPs in the person being vaccinated mimics a natural infection, stimulating the immune system to recognize, prevent, and control the target infection.
In human clinical trials of the company’s HIV vaccines (which have completed Phase IIa trials), GeoVax has demonstrated that MVA-VLPs are safe and can elicit strong and durable antibody and cellular immune responses to fight HIV infections.
For the Zika virus (ZIKV), GeoVax is working in collaborations with the University of Georgia Research Foundation and the Centers for Disease Control.
With the CDC, the company has developed an animal model and has performed mouse efficacy studies. ZIKV and reagents will be supplied by the University of Texas Medical Branch.
MVA has been safely administered to 120,000 humans in Germany in a campaign for eradication of smallpox in the 60s and later as a vector for delivery of other vaccines including HIV, malaria and tuberculosis, says Farshad Guirakhoo, Ph.D., chief scientific officer of GeoVax.
“Our Zika vaccine has shown 100% protection against death in a mouse model after a single inoculation,” he says. “MVA has been adapted to replicate in chickens, so when it is used in humans as a vector for delivery of other vaccine target antigens, the virus can’t reproduce infectious progeny to spread in the host, making it highly safe for people.”
Unlike other companies that are using viruses to create a Zika vaccine, Inovio is developing a DNA-based monoclonal antibody. This DNA-based monoclonal antibody technology has the potential to lead to products that can be designed and manufactured on a large scale using common fermentation technology. Inovio’s DNA-based immunotherapy platform can target both immediate therapy through delivery of dMAb products as well as long-term immunity via DNA vaccination.
LINK
http://www.pharmavoice.com/article/2017-2-zika-research/
Recent GOVX News
- GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine • GlobeNewswire Inc. • 04/04/2024 04:30:00 PM
- GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress • GlobeNewswire Inc. • 03/28/2024 01:00:00 PM
- GeoVax to Present at the 36th Annual Roth Conference • GlobeNewswire Inc. • 03/12/2024 01:00:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 03/11/2024 08:13:14 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/11/2024 04:15:24 AM
- GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System • GlobeNewswire Inc. • 03/06/2024 02:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/01/2024 09:08:47 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 09:05:14 PM
- GeoVax Reports 2023 Year-End Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:41:26 PM
- GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 • GlobeNewswire Inc. • 02/22/2024 02:00:00 PM
- GeoVax to Present at the 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/19/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:01:35 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:25 PM
- GeoVax Announces Multiple Patent Issuances and Allowances • GlobeNewswire Inc. • 02/13/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:43:48 PM
- GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster • GlobeNewswire Inc. • 02/06/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 06:13:27 PM
- GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement • GlobeNewswire Inc. • 01/29/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:03:40 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/12/2024 09:00:38 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM